Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
They are both administered as a once-weekly subcutaneous injection, but they have different FDA-approved indications and insurance coverage
That said, the landscape is shifting quickly
These reference points come from preclinical literature and small pilots
GLP-1 receptor agonists suppress pro-inflammatory cytokines
A study of the SORL1 gene in the pathogenesis of late-onset Alzheimers disease by affecting the expression of BDNF
Retatrutide redesigns multi-agonism Approval Outlook Neither CagriSema nor Retatrutide should be treated as FDA-approved therapy in 2026 until regulators say otherwise
US$ 26.11
US$ 22.44
US$ 21.22
